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Background: Carfilzomib (CFZ) is a proteasome inhibitor that selectively and irreversibly binds to its target and
has been approved in the US for treatment of relapsed and refractory multiple myeloma. Phase 1B studies of CFZ
reported signals of clinical activity in solid tumors, including small cell lung cancer (SCLC). The aim of this study was
to investigate the activity of CFZ in lung cancer models.
Methods: A diverse panel of human lung cancer cell lines and a SHP77 small cell lung cancer xenograft model
were used to investigate the anti-tumor activity of CFZ.
Results: CFZ treatment inhibited both the constitutive proteasome and the immunoproteasome in lung cancer cell
lines. CFZ had marked anti-proliferative activity in A549, H1993, H520, H460, and H1299 non-small cell lung cancer
(NSCLC) cell lines, with IC50 values after 96 hour exposure from <1.0 nM to 36 nM. CFZ had more variable effects in
the SHP77 and DMS114 SCLC cell lines, with IC50 values at 96 hours from <1 nM to 203 nM. Western blot analysis of
CFZ-treated H1993 and SHP77 cells showed cleavage of poly ADP ribose polymerase (PARP) and caspase-3, indicative
of apoptosis, and induction of microtubule-associated protein-1 light chain-3B (LC3B), indicative of autophagy. In
SHP77 flank xenograft tumors, CFZ monotherapy inhibited tumor growth and prolonged survival, while no additive
or synergistic anti-tumor efficacy was observed for CFZ + cisplatin (CDDP).
Conclusions: CFZ demonstrated anti-proliferative activity in lung cancer cell lines in vitro and resulted in a significant
survival advantage in mice with SHP77 SCLC xenografts, supporting further pre-clinical and clinical investigations of
CFZ in NSCLC and SCLC.
Keywords: Carfilzomib, Proteasome inhibitor, Lung cancer, CisplatinBackground
Over the last several decades, proteasome inhibition has
been extensively investigated as a selective anti-cancer
strategy and validated in clinical trials using first and
second generation proteasome inhibitors (PIs) [1]. In-
hibition of the proteasome can induce disturbances in
signal transduction, apoptosis regulation, cell cycle con-
trol, transcriptional regulation, and inflammation [2]. A
dominant mechanism of action that contributes to the
anti-tumor activity of proteasome inhibition is the
down-regulation of proto-oncogenic nuclear factor* Correspondence: abaker@uacc.arizona.edu
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unless otherwise stated.kappa B (NF-кB) signaling through the blocking of inhibi-
tory factor kappa B (I-кB) degradation; inhibition of
NF-кB signaling reduces expression of pro-inflammatory
response genes and upregulates several cycle-dependent
kinase inhibitors, promoting tumor cell apoptosis [3].
Other mechanisms by which proteasome inhibitors induce
tumor cell apoptosis include phosphorylation and cleavage
of the anti-apoptotic factor Bcl-2, stabilization of p53,
interference with the unfolded protein response leading
to endoplasmatic reticulum stress, and activation of
TNF-related apoptosis-inducing ligand-induced apoptosis
through increased death receptors DR4 and DR5 [4-7].
Inhibition of the proteasome has proven to be an
effective therapeutic strategy for multiple myeloma and
mantle cell lymphoma [8,9]. There has been interest inhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tumors, including lung cancer. Bortezomib (BTZ), the
first-in-class Food and Drug Administration approved
PI, has been investigated in preclinical models and in
clinical trials as an anti-cancer therapeutic for lung can-
cer. While BTZ showed potent in vitro activity in a wide
range of non-small cell lung cancer (NSCLC) cell lines
and demonstrated significant in vivo activity [10], clinical
trials with BTZ monotherapy and in combination with
chemotherapy or targeted agents in chemotherapy-naïve
and previously-treated NSCLC patients yielded overall
mixed results [11-18]. In the setting of relapsed/refrac-
tory small cell lung cancer (SCLC), a clinical trial of
BTZ reported limited single-agent activity [19].
Carfilzomib (CFZ) is a selective PI that is approved in
the United States for the treatment of relapsed and re-
fractory multiple myeloma (RRMM). CFZ binds irrevers-
ibly to its target, resulting in sustained inhibition, which
is in contrast to the reversible, boronate-based PIs, such
as BTZ and MLN9708 [20-23]. CFZ selectively inhibits
the chymotrypsin-like activity of the constitutive prote-
asome and the immunoproteasome [21,22]. CFZ, unlike
BTZ, has minimal off-target effects on non-proteasome,
serine proteases including cathepsin A, cathepsin G,
chymase, dipeptidyl peptidase II, and HtrA2/Omi, which
is thought to underlie its favorable toxicity profile with
less neurotoxicity than BTZ [24]. CFZ overcomes BTZ
resistance in some preclinical models, suggesting that se-
lective, irreversible PIs without dose-limiting neurotox-
icity may lead to more potent antitumor response and
an improved tolerability profile compared with reversible
PIs [25]. A phase I/II study of CFZ reported a durable
partial tumor response in a patient with heavily pre-
treated SCLC [26]. Additionally, CFZ has shown clinical
activity in some BTZ-treated patients [27,28].
While novel targeted therapy has proven effective in a
subset of NSCLC patients, mainly never smokers, there
are relatively limited therapeutic options after failure of
first-line regimens for both NSCLC and SCLC related
to intrinsic and acquired mechanisms of resistance to
chemotherapy. There continues to be interest in devel-
oping novel molecularly targeted therapeutic strategies
for lung cancer. Given the potential for improved effi-
cacy and greater tolerability of CFZ, we investigated the
anti-tumor activity of CFZ in NSCLC and SCLC cell
line models alone and in combination with cis-
diammineplatinum (II) dichloride (cisplatin, CDDP). We
report that proteasome inhibition with CFZ resulted in
potent in vitro growth inhibition and induction of apop-
tosis across a diverse set of lung cancer cell lines and
in vivo tumor growth inhibition in a SCLC xenograft
model. However, the combination of CFZ with CDDP
was not additive or synergistic in a number of cell lines
and a SCLC xenograft, suggesting that other rationalcombinations of CFZ with chemotherapy or targeted
agents be investigated.Methods
Reagents and antibodies
CFZ, provided by Onyx Pharmaceuticals, Inc., an Amgen
subsidiary (South San Francisco, CA), was dissolved in
dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO)
at a stock concentration of 10 mM and stored at −20°C. A
stock concentration of 3.3 mM CDDP in saline (Teva
Pharmaceuticals, Israel) was stored at −20°C. Anti-
bodies against poly ADP ribose polymerase (PARP),
cleaved caspase-3, p-glycoprotein (Pgp; MDR1), and B-cell
lymphoma 2 (Bcl-2) were purchased from Cell Signal-
ing Technology (Beverly, MA). Antibodies against
microtubule-associated protein-1 light chain-3B (LC3B)
were obtained from Sigma-Aldrich. Alpha-tubulin anti-
bodies were purchased from Calbiochem (La Jolla, CA).
The secondary antibodies, HRP-conjugated goat anti-
rabbit and HRP-conjugated goat anti-mouse, were
purchased from Jackson ImmunoResearch (West
Grove, PA).Cell lines
All NSCLC (NCI-H520, A549, NCI-H1993, NCI-H460,
and NCI-H1299) and SCLC (SHP77 and DMS114) cell
lines were obtained from the American Tissue and
Cell Collection (ATCC). These cells represent different
pathological subtypes (squamous, adenocarcinoma, car-
cinoma) with SCLC cells derived from both metastatic
lesions (SHP77) and a primary tumor (DMS114). A var-
iety of molecular characteristics are also represented in-
cluding wild-type p53 (H549, H460), reduced or deleted
p53 (H520, H1299), wild-type KRAS (H1299), mutated
KRAS (A549, H460), wild-type EGFR (A549), mutated
EGFR (H1993, H460), and amplified c-met (H1993). All
cells were cultured in RPMI 1640 (Cellgro) with 10%
fetal bovine serum (FBS), 1 mM sodium pyruvate, and
10 mM HEPES. SHP77 cells were maintained in a simi-
lar manner except that heat-inactivated FBS was used.
All cells were grown in 5% CO2 at 37°C in a humidified
tissue culture incubator. Cells were routinely tested for
mycoplasma contamination using a MycoAlert myco-
plasma detection kit (Lonza, Rockland, ME) and were
found to be negative. To verify cell line authenticity,
genomic DNA was extracted (Sigma GIN70-KT), diluted
appropriately in TE buffer, and submitted to the
University of Arizona Genomics Core (Human Origins
Gentoyping Lab) for analysis. Autosomal short tandem
repeat typing was conducted across the 13 core STRs in
CODIS and referenced against allelic peaks in cell lines
of previously confirmed genotype. All cell lines were
verified as authentic.
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Cells were seeded in 96-well plates and incubated over-
night. Cultures were exposed to various concentrations
of CFZ or CDDP for the specified treatment intervals.
Proliferation of adherent cells was determined by 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) assay. Proliferation of suspension cells was de-
termined by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)
assay. For adherent cultures, MTT dye (2 mg/ml) was
added, and the cells were incubated for an additional
4 hours at 37°C. After removal of medium, the resulting
formazan crystals were dissolved in DMSO (Sigma-
Aldrich) for 5 minutes and the plates were read in a
spectrophotometer at 540 nm. For suspension cul-
tures, MTS dye (0.37 mg/mL) was added. The cells
were incubated for 4 hours and then read spectrophoto-
metrically at 490 nm. Dose response curves were created
using GraphPad Prism version 5.01 (GraphPad Software
Inc, La Jolla, CA). IC50 values were calculated using
CalcuSyn (Biosoft, Great Shelford, Cambridge, UK).Proteasome subunit quantification
The proteasome constitutive/immunoproteasome sub-
unit enzyme-linked immunosorbent (ProCISE) assay was
used to quantitate individual constitutive (β5, β1, and
β2) and immunoproteasome (LMP7, LMP2, and
MECL1) subunits [29]. Briefly, cell lysate was incubated
with a biotinylated proteasome active-site binding probe
(PABP). Lysate was then denatured, and subunits bound
to PABP were isolated with streptavidin-conjugated
sepharose beads. Individual subunits were probed with
subunit-specific primary antibodies, followed by HRP-
conjugated secondary antibodies. A chemiluminescent
substrate was used to generate a luminescent signal as-
sociated with bound HRP, which was read on a lumin-
ometer. Absolute values of subunit per microgram of
total protein were determined based on a purified prote-
asome standard curve. Statistical significance was deter-
mined by Student’s t test.Cell viability
Cells were seeded in 6-well plates and incubated over-
night. Cultures were left untreated or treated with pre-
determined IC50 doses of CFZ or CDDP and incubated
for an additional 48, 72, or 96 hours. After each time
point, the media containing any non-adherent cells was
collected. Adherent cells were then detached using tryp-
sin, suspended in culture medium, and disaggregated by
manual pipetting. After mixing all collected cells with
trypan blue (Thermo Scientific), viable cells that ex-
cluded the dye and dead cells that stained an intense
blue were counted using a hemocytometer.Western blot analysis
After various time points, the cells were rinsed with cold
phosphate buffered saline (PBS) and harvested in a buf-
fer containing 50 mM Tris HCl (pH 8.0), 150 mM NaCl,
1% Triton X-100, 2 mM EDTA, 5 mM Na3VO4, 200 μM
NaF, 21 μM leupeptin, 230 nM aprotinin, and 1 mM
phenylmethylsulfonyl fluoride (PMSF). The cell lysate
was sonicated and centrifuged at 10,000 × g for 10 min
at 4°C. Protein concentration of the resulting super-
natant was determined using a 660 nm Protein Assay kit
(Thermo Scientific, Rockford, IL). Twenty micrograms
of total cell lysate were boiled for 5 min and resolved in
a 10% acrylamide/bisacrylamide gel by electrophoresis at
125 V for 105 min. Proteins were then transferred to a
polyvinylidene fluoride (PVDF) membrane (Millipore,
Billerica, MA). Membranes were blocked with 5% milk
in Tris-buffered saline containing 0.1% Tween-20
(TBST) for 30 min before overnight incubation at 4°C
with various primary antibodies, typically at a 1:1000
dilution. Blots were rinsed with TBST and incubated for
2 hours at room temperature with secondary antibody at a
1:15,000 dilution. Reactive bands were visualized by expos-
ure to film using Pierce Supersignal West Pico HRP
Detection Reagent (Thermo Fisher Scientific, Rockford IL).
Blots were stripped in 0.2 M NaOH with shaking for
10 min at room temperature and then re-probed for
loading control.
Drug combination studies
Cells were seeded as described in the proliferation assay
section and treated with various concentrations of CFZ
and CDDP either simultaneously, CDDP followed by
CFZ, or CFZ followed by CDDP. Simultaneously-treated
cells were incubated for 96 hours before being analyzed.
For CDDP/CFZ, cells were treated with CDDP for
24 hours, followed by CFZ for an additional 72 hours
before analysis. For CFZ/CDDP, cells were first treated
with CFZ for 48 hours, then with CDDP for an add-
itional 48 hours before analysis. For sequential drug
treatments, the first drug remained in the media as the
second drug was added. The range of concentrations
used for each drug was 4.5 nM to 30 μM. The upper
dose (30 μM) is near the estimated blood concentration
of CDDP found in patients following administration of
the dosage that is used clinically (100 mg/m2) [30]. In-
teractions between CFZ and CDDP were analyzed using
the median effect method of Chou and Talalay [31]. In
this method, dose–response curves are generated for
each agent individually. These results are then used to
analyze the results obtained from the combination treat-
ment. A combination index (CI) was generated using
CalcuSyn software (Biosoft, Cambridge, United Kingdom)
and synergy level classifications were assigned as de-
scribed in the CalcuSyn manual. A CI of less than 1
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cates additive effects, and a CI of more than 1 is indica-
tive of antagonistic effects (>3, strong antagonism).In vivo SHP77 xenograft studies
Studies were performed under approved protocols in ac-
cordance with Institutional Animal Care and Utilization
Committee guidelines. SHP77 (107) cells were subcuta-
neously injected into flanks of female scid mice. When
tumors became palpable (average tumor volume be-
tween 200–300 mm3), mice were randomized into four
treatment groups: 1) Control - vehicle only, 2) CFZ -
3 mg/kg intravenous (IV) injection for two consecutive
days for the first week followed by 5 mg/kg IV for two
consecutive days repeated weekly until death or sacrifice,
3) CDDP – 4 mg/kg intraperitoneal (IP) injection once
per week for 3 weeks, and 4) CFZ – 5 mg/kg IV +
CDDP – 4 mg/kg IP. For combination treatment, CFZ
(3 mg/kg the first week and 5 mg/kg on subsequent
weeks) was given on days 1 and 2 of each week and
CDDP was given on day 5 for 3 weeks. Animals were
euthanized when tumors reached 2000 mm3 or became
necrotic. A separate group of mice bearing SHP77 flank
xenografts (200–500 mm3) were randomized into a ve-
hicle control group or CFZ (5 mg/kg IV) dose group
(N = 4) and treated for two consecutive days. 48 hours
later, mice were euthanized and tumors were removed
and fixed in 10% buffered formalin for pharmacody-
namic biomarker analysis.Histology and immunohistochemistry
SHP77 flank xenograft tumors were excised and imme-
diately fixed in 10% PBS buffered formalin. Tissues were
transferred to 70% ethanol within 24 hours and embed-
ded in paraffin within 3 days. Sectioned tissue sections
(0.3 micron slices) were prepared for hematoxylin and
eosin (H&E) staining or immunohistochemistry (IHC)
from formalin fixed, paraffin embedded (FFPE) blocks.
IHC was performed using cleaved caspase-3 antibody
(#9661, Cell Signaling, Danvers, MA) diluted 1:400. Tis-
sue sections were stained on a Discovery XT automated
system (Ventana Medical Systems, Inc, Tucson, Arizona)
using proprietary reagents. Cleaved caspase-3 was de-
tected using the Ventana Anti-Rabbit Secondary Anti-
body for 16 minutes. Labeling was visualized with the
Ventana OmniMap kit followed by counterstaining with
hematoxylin. Slides were then dehydrated and coverslips
were added as per normal laboratory protocol. Images
were acquired using an Olympus BX50 microscope and
an Olympus DP72 digital camera with CellSens Digital
Image software. One pathologist (Dr. Raymond Nagle,
University of Arizona Cancer Center) evaluated each
slide and scored the percentage of cells staining positive.Results
CFZ suppresses proliferation in a range of NSCLC and
SCLC cell lines
A panel of 7 cell lines was used to model the anti-tumor
effects of CFZ treatment in lung cancer. We sought to
determine the in vitro profile of CFZ sensitivity in these
cells as compared to CDDP, a platinum-based com-
pound commonly used in lung cancer treatment regi-
mens. MTT or MTS assays were performed on cell lines
following 48 or 72 hour treatments. Results from one
representative experiment (n = 6) are shown in Figure 1.
In each of the cell lines tested, CFZ was more potent
than CDDP in inhibiting cell growth. Only slight inhibi-
tory effects were seen at 24 hours, and growth curves at
96 hours were similar to the 72-hour curves (data not
shown). IC50 values were calculated from the 48, 72, and
96-hour growth curves (Table 1). The IC50 values for cell
lines treated with CFZ were in the low nanomolar range.
In contrast, the IC50 values for CDDP treated cells lines
were in the micromolar range. CFZ maximal growth
inhibition improved over time, reflected by a decreasing
IC50, for all cell lines with the exception of SHP77 cells,
which showed a 60% increase in the IC50 value between
48 and 72 hour treatments.
CFZ inhibits proteasome subunits in lung cancer cell lines
The ProCISE assay was used to determine which prote-
asome subunits are inhibited by CFZ in lung cancer cell
lines. This immunosorbent assay-based method provides
accurate quantitation of proteasome subunits within
cell lysate [29]. The abundance of the chymotrypsin-like
(CT-L), caspase-like (C-L), and trypsin-like (T-L) sub-
units of both the constitutive and immunoproteasome
was quantified in various NSCLC and SCLC cell lines.
Similar to results reported with other cell types [29],
CFZ selectively inhibits the CT-L activity of the prote-
asome in multiple lung cancer cell lines. The activities of
the β5 subunit of the constitutive proteasome and the
LMP7 subunit of the immunoproteasome were signifi-
cantly reduced in both the H1993 (NSCLC) and SHP77
(SCLC) cell lines when treated with the predetermined
IC50 doses of CFZ for 48 hours (Figure 2). Another
NSCLC cell line (A549) was tested with similar results
(data not shown).
CFZ reduces cell viability while inducing apoptosis and
autophagy
To determine the cytotoxic effects of CFZ in lung cancer
cell lines, the H1993 NSCLC and SHP77 SCLC cells
were treated with predetermined 48 hour IC50 doses.
Cells were collected at 48, 72, and 96 hour time points
and analyzed for viability (Figure 3A). Results demon-
strate a strong sensitivity to CFZ in vitro with a 40-60%



























































































































Figure 1 Dose response curves illustrate the effect of CFZ and CDDP on the growth of lung cancer cell lines. Cells were exposed to CFZ or
CDDP at various concentrations for 48 or 72 hours and assayed by MTT or MTS as described in the Methods section. One representative experiment is
shown, n = 6.
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To determine whether the observed reduction in viabil-
ity with CFZ treatment occurred via the induction of
apoptosis, levels of cleaved PARP and cleaved caspase-3
were evaluated by Western blot. As with CDDP, treat-
ment with CFZ showed induction of these apoptotic
markers (Figure 3B).Some studies suggest that one possible mechanism of
resistance to proteasome inhibition is induced autopha-
gic flux [32]. To profile autophagy in our lung cancer
cells we examined LC3B which is present in its cytoplas-
mic form (LC3B-I) or is directly associated with the
plasma membrane of autophagosomes (LC3B-II). We
noted increased LC3B-II, a marker of autophagy, at 24,
Table 1 Sensitivity of lung cancer cell lines to CFZ and CDDP
Cell line
CFZ IC50 (μM) CDDP IC50 (μM)
48 h 72 h 96 h 48 h 72 h 96 h
NSCLC
H520 0.0769 0.0299 0.0083 19.43 23.24 18.15
A549 0.0901 0.0716 0.0047 25.97 26.53 9.01
H1993 0.0277 0.0172 0.0216 29.60 19.58 15.52
H460 0.1657 0.0631 0.0364 9.02 3.72 2.69
H1299 0.0500 0.0293 <0.0001 >30.0 8.81 3.53
SCLC
SHP77 0.0614 0.0994 0.2031 12.17 21.55 28.57
DMS114 0.0007 0.0002 <0.0001 13.13 8.10 3.47
The determined inhibitory concentrations (IC50 values) represent the level of drug that inhibited cell growth by 50%. IC50 values (μM) of CFZ at 48 and 72 hours
are the mean of two or more independent experiments, n ≥ 12. Other IC50 values are the mean of one experiment, n = 6.
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data not shown). A larger increase in LC3B-II was found
in the more CFZ-resistant SHP77 cell line as compared
to the more CFZ-sensitive H1993 cell line.
Effects of combining CFZ and CDDP in lung cancer cell lines
Because CDDP is frequently used as part of standard
front-line chemotherapy regimens in NSCLC and SCLC,
we investigated the combined activity of CFZ and CDDP
when added simultaneously for 96 hours on inhibition
of cell proliferation using the MTT or MTS assay
(Table 2). This combination had mixed results, with an-
tagonism observed in H520 and H1993 cell lines and
modest synergy observed in the H460 and SHP77 cell
lines. Cell characteristics, such as mutations of EGFR or
K-Ras, may alter the effectiveness of first–line platinum-
based chemotherapy [33]. To investigate whether se-
quential administration of agents could improve activity,
we treated with CDDP for 24 hours, followed by
addition of CFZ for 72 hours, or CFZ for 48 hours
followed by addition of CDDP for 48 hours. The first




Figure 2 The c20S subunit β5 and the i20S subunit LMP7 are inhibited in
48 hours with CFZ (48 hour IC50 dosage) were evaluated using the ProCISE assa
pseudo-replicates. Results were statistically significant (***p < 0.001, **p < 0.01) uadded. Results were similar regardless of sequence, with
antagonism (decrease in efficacy) observed in all cell
lines except the H460 cells when CFZ was administered
first; in SHP77 cells there was synergy observed regard-
less of sequencing. Synergy values were not calculated in
the H1299 or DMS114 cell lines due to the almost
complete inhibition of proliferation observed from com-
bination treatments.
In vivo growth inhibition and survival
Groups of scid mice (n = 8) were used to evaluate
in vivo tumor responses to CFZ. Treatment with CFZ
monotherapy resulted in tumor growth delay and a sig-
nificant survival advantage in mice bearing flank SHP77
tumors (Figure 4A,B). Treatment with monotherapy
CDDP caused a tumor growth delay, but failed to show
a significant survival advantage (Figure 4A,C). Similarly,
the combination of CFZ and CDDP demonstrated a
tumor growth delay, but no significant survival advan-
tage (Figure 4A, D). It should be noted that the dose of
CDDP used was modest in order to minimize toxicity




CFZ treated H1993 and SHP77 cells. Cells left untreated or treated for
y to determine the level of uninhibited subunits. Mean ± SD are from three
sing Student’s t-test.


































Figure 3 CFZ treatment reduces cell viability through induction of apoptosis and can induce autophagy. Cells were left untreated or
exposed to CFZ or CDDP at the 48 hour IC50 dose. A) Viability at 48, 72, and 96 hours was determined by direct cell counting after trypan blue
staining. Mean ± SD are shown (n = 4). B) Detection of PARP, cleaved PARP, cleaved caspase-3, and C) LC3B by immunoblot in total extracts of
cells harvested at 24, 48, and 72 hours. Boxed areas highlight the level of LC3B-II in CFZ treated cells which is a marker of autophagy. α-tubulin is
shown as a loading control.
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Table 2 Inhibitory activity of CFZ combined with CDDP in lung cancer cell lines
Cell line
Simultaneous CDDP→CFZ CDDP→CFZ
IC50 (nM) Synergy Value IC50 (nM) Synergy Value IC50 (nM) Synergy Value
NSCLC
H520 14.5 Ant. 427.3 Ant. + 87.6 Ant. +
A549 <1 NC 206.2 Ant. + 72.3 Ant. +
H1993 173.1 Ant. + 134.0 Ant. + 200.6 Ant. +
H460 14.8 Syn. 258.3 Ant. + 25.1 Syn.
H1299 <1 NC <1 NC <1 NC
SCLC
SHP77 72.8 Syn. 171.8 Syn. 21.7 Syn. +
DMS114 <1 NC <1 NC <1 NC
Cells were treated with equivalent doses of CFZ and CDDP either simultaneously, CDDP followed by CFZ, or CFZ followed by CDDP and evaluated 96 hours after initial
treatment. IC50 values represent the concentration at which the drug combination inhibited cell growth by 50%. Synergy values were determined with Calcusyn
software from the combination index (CI) method described by Chou and Talalay [31]. CI interpretation: <0.3 strong synergism (Syn. +), 0.3-0.9 synergism (Syn.),
1–3 antagonism (Ant.), >3 strong antagonism (Ant. +), or not calculated due to high cell death at lowest dose (NC).
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CDDP treatment, with deaths being judged to be likely
drug-related. Due to the potency observed with CFZ
treatment in the DMS114 cell line, we attempted to
grow this cell line as flank xenografts in scid mice to
investigate CFZ in vivo efficacy in this model. Unfortu-
nately, we were not able to observe any palpable tumors
up to 60 days post-cell inoculation. To determine if CFZ
was inducing apoptosis in vivo, we analyzed activation
and cleavage of caspase-3 in SHP77 xenograft tumors
(Figure 4E). A pathologist score showed a significant
increase in cleaved caspase-3 in the CFZ treated xeno-
grafts versus the vehicle treated xenografts.
Conclusions
Pre-clinical studies with the first generation reversible
proteasome inhibitor BTZ showed that BTZ caused pro-
teasome inhibition that was associated with diminished
cell proliferation and increased cell death across a wide
variety of NSCLC models [13]. Similarly, we found that
CFZ inhibits cell proliferation and induces apoptotic
markers in a pathologically and molecularly diverse
panel of lung cancer models, including SCLC. IC50
values for the cell lines treated with CFZ were all in the
low nanomolar range (Table 1). This is similar to the re-
ported BTZ IC50 values (30–62.5 nM) found in many of
these cell lines [3,34].
In vitro testing revealed differences between the
SHP77 cells and the other cell lines tested. While the
CFZ IC50 value decreased over time for all other cell
lines tested, the IC50 value increased over time for the
SHP77 cells, suggesting upregulation of a resistance
mechanism or selection of an intrinsically resistant
population of cells (Table 2). One explanation for this
observation could be the expression of P-glycoprotein
(Pgp, MDR1), a drug efflux pump recognized as a majorchemotherapy resistance mechanism [35]. Unlike BTZ
[36], CFZ has been reported to be a substrate for Pgp
[37] and resistance may therefore be mediated by Pgp
expression. The SHP77 cells grown in vitro express high
levels of Pgp as compared to the other cell lines tested
(Additional file 1: Figure S1). However, no change in Pgp
expression was observed for CFZ treated SHP77 cells
over a 96 hour period (data not shown). Therefore the
SHP77 resistance mechanism(s) responsible for the
increasing IC50 value over time for CFZ monotherapy
remains unidentified.
We further investigated the efficacy of CFZ using the
SHP77 cells in a xenograft model. Because synergy was
observed during CFZ and CDDP treatment in the
SHP77 cells (Table 2), we investigated both monotherapy
and combined activity with CDDP in vivo. In spite of
Pgp expression in the SHP77 cells, in vivo treatment re-
sulted in tumor growth inhibition and a significant sur-
vival advantage (Figure 4). This coincided with increased
cleaved caspase-3 found in xenograft tumor cells. Unlike
in vitro where synergistic activity with CDDP was ob-
served, the combination of CFZ and CDDP in vivo did
not result in additive growth inhibition or a survival ad-
vantage over CFZ monotherapy. It is possible that the
in vivo tumor microenvironment, which has different
levels of growth factors and oxygen supply than cell cul-
ture may abrogate cisplatin efficacy and therefore not
yield similar results to in vitro studies. Clinically, resist-
ance to cisplatin is common in SCLC.
The lack of additive activity with CFZ and CDDP may
be due to activation of survival signaling in response to
CDDP and/or CFZ. There are multiple mechanisms by
which cells acquire resistance to CDDP (reviewed by
Galluzzi et al. [38]). Upregulation of heat shock proteins,
which has been previously reported in response to prote-
































Figure 4 In vivo responses of SHP77 xenografts to CFZ and CDDP. Groups of scid mice (n = 8) were treated as detailed in the Methods section.
(A) Mean tumor growth curves of SHP77 xenografts. The x-axis depicts days post tumor cell injection. Drug treatment was initiated on day 20 as
indicated by arrow. (B, C, D) Kaplan-Meier survival curves of SHP77 tumor bearing mice for control and CFZ treated, control and CDDP treated, and
control and CFZ/CDDP combination treated groups. The log-rank (Mantel-Cox) test was performed to evaluate the differences in survival between
groups. A significant difference (p < 0.05) in survival was found between the control and CFZ treated groups. (E) SHP77 xenograft groups
(n = 4) were treated two consecutive days with either vehicle or CFZ (5 mg/kg). Tumors were harvested 48 hours after the second dose and
fixed sections were processed for immunohistochemical analysis. Representative photographs of immunoreactivity for cleaved caspase-3 at
magnification of 60× and 400× are shown. Scale bar on 400× images = 50 μm. The percent of cells with cleaved caspase-3 is significantly
higher in the CFZ treated tumors versus the vehicle treated tumors (*p < 0.05 using Student’s t-test).
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shown to be associated with acquired cisplatin resistance
in the A549 NSCLC cell line [40]. We saw increased ex-
pression of LC3B-II, a putative marker of autophagy, in
response to both CFZ and CDDP treatment in vitro in
the SHP77 and H1993 cell lines (Figure 3C). Thisobservation suggests that induction of autophagy by
CFZ could contribute to the abrogated efficacy of
CDDP.
Gaining a greater understanding of resistance mecha-
nisms to proteasome inhibition will be important in
further developing CFZ as a lung cancer therapeutic.
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to BTZ have been described [41-43]. In lung cancer cell
lines, cross resistance to BTZ and CFZ has been ob-
served in A549 and SW1753 cells, but not in H460 BTZ
resistant cells. In these studies, resistance to BTZ was
associated with mutant β-subunits within the prote-
asome core [41]. Resistance to BTZ has also been associ-
ated with basal proteasome levels [41]. We did not
observe this trend when comparing the basal β5 and
LMP7 subunit levels with the corresponding CFZ IC50
values of the H1993 and SHP77 cell lines (Figure 1,
Table 1) or with the A549 cells (data not shown).
Bcl-2 over-expression in SCLC has been linked with
chemotherapy resistance [44]. Bortezomib has been
shown to reduce Bcl-2 levels and induce apoptosis in the
H526 SCLC cell line [45]. In the A549 spheroid model,
Bcl-2 upregulation has been associated with BTZ resist-
ance [46]. In head and neck cancer models CFZ resist-
ance was associated with increased levels of the Bcl-2
family member, Mcl-1 [47]. When CFZ is combined with
obatoclax, a pan-BH3 mimetic that inhibits Mcl-1, en-
hanced apoptosis is observed in diffuse large B-cell
lymphoma cell lines [48]. Although treatment with CFZ
or CPPD did not significantly modulate Bcl-2 levels in the
H1993 or SHP77 cells (Additional file 1: Figure S2), future
studies should investigate the combined activity of CFZ
with Bcl-2 and/or Mcl-1 inhibitors in lung cancer.
We did not directly compare the anti-proliferative ac-
tivity of BTZ to CFZ in the current study. However, pre-
vious studies suggest that BTZ and CFZ have similar
in vitro activity in lung cancer cell lines [41]. Because
CFZ displays greater specificity and has a different phar-
macokinetic profile than BTZ; CFZ may have different
activity than BTZ in clinical lung cancer studies [49].
One of the major dose-limiting toxicities of BTZ is per-
ipheral neuropathy (PN). CFZ use is associated with
much lower new-onset PN [50], making it a more at-
tractive agent in the clinic. CFZ, unlike BTZ, does not
induce neurodegeneration in vitro, which may explain
its lower rates of PN in clinical trials [24]. CFZ over-
comes BTZ resistance, suggesting that selective, irrevers-
ible PIs without dose-limiting neurotoxicity may lead to
more potent antitumor response and an improved toler-
ability profile compared with reversible PIs [25].
Single-agent CFZ has been approved in the US for
treatment of RRMM based on its efficacy and lack of cu-
mulative toxicities [27]. Our findings reported here sup-
port further investigation of CFZ in novel combinations
with chemotherapy and targeted agents in SCLC and
NSCLC pre-clinical models to help guide the clinical de-
velopment of CFZ in lung cancer. In addition, further
delineation of resistance mechanisms to proteasome in-
hibition may aid in selection of lung cancer patients for
CFZ-based therapy.Additional file
Additional file 1: Figure S1. Relative Pgp expression in lung cancer cell
lines. Total cell lysate from untreated cells were probed for expression of
Pgp. The blot was reprobed for α-tubulin as a loading control. Figure S2.
Analysis of Bcl-2 expression in H1993 and SHP77 cells. Cells were left
untreated or exposed to CFZ or CDDP at the 48 hour IC50 dose. Levels of
Bcl-2 were determined by immunoblot in total extracts of cells harvested at
24, 48, and 72 hours. α-tubulin is shown as a loading control.
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